Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation
Genre
Journal articleDate
2018-01-27Author
Rom, SlavaZuluaga-Ramirez, Viviana
Reichenbach, Nancy L.
Erickson, Michelle A.
Winfield, Malika
Gajghate, Sachin
Christofidou-Solomidou, Melpo
Jordan-Sciutto, Kelly L.
persidsky, yuri
Group
Center for Substance Abuse Research (Temple University)Department
Pathology and Laboratory MedicineSubject
Secoisolariciresinol Diglucoside (SDG)Brain microvascular enothelial cells (BMVEC)
Primary human monocytes
Aseptic encephalitis
Main lignan
Permanent link to this record
http://hdl.handle.net/20.500.12613/8782
Metadata
Show full item recordDOI
https://doi.org/10.1186/s12974-018-1065-0Abstract
Background: Secoisolariciresinol diglucoside (SDG), the main lignan in flaxseed, is known for its beneficial effects in inflammation, oxidative stress, heart disease, tumor progression, atherosclerosis, and diabetes. SDG might be an attractive natural compound that protects against neuroinflammation. Yet, there are no comprehensive studies to date investigating the effects of SDG on brain endothelium using relevant in vivo and in vitro models. Methods: We evaluated the effects of orally administered SDG on neuroinflammatory responses using in vivo imaging of the brain microvasculature during systemic inflammation and aseptic encephalitis. In parallel, the anti-inflammatory actions of SDG on brain endothelium and monocytes were evaluated in vitro blood-brain barrier (BBB) model. Multiple group comparisons were performed by one-way analysis of variance with Dunnet’s post hoc tests. Results: We found that SDG diminished leukocyte adhesion to and migration across the BBB in vivo in the setting of aseptic encephalitis (intracerebral TNFα injection) and prevented enhanced BBB permeability during systemic inflammatory response (LPS injection). In vitro SDG pretreatment of primary human brain microvascular endothelial cells (BMVEC) or human monocytes diminished adhesion and migration of monocytes across brain endothelial monolayers in conditions mimicking CNS inflammatory responses. Consistent with our in vivo observations, SDG decreased expression of the adhesion molecule, VCAM1, induced by TNFα, or IL-1β in BMVEC. SDG diminished expression of the active form of VLA-4 integrin (promoting leukocyte adhesion and migration) and prevented the cytoskeleton changes in primary human monocytes activated by relevant inflammatory stimuli. Conclusion: This study indicates that SDG directly inhibits BBB interactions with inflammatory cells and reduces the inflammatory state of leukocytes. Though more work is needed to determine the mechanism by which SDG mediates these effects, the ability of SDG to exert a multi-functional response reducing oxidative stress, inflammation, and BBB permeability makes it an exciting potential therapeutic for neuroinflammatory diseases. SDG can serve as an anti-inflammatory and barrier-protective agent in neuroinflammation.Citation
Rom, S., Zuluaga-Ramirez, V., Reichenbach, N.L. et al. Secoisolariciresinol diglucoside is a blood-brain barrier protective and anti-inflammatory agent: implications for neuroinflammation. J Neuroinflammation 15, 25 (2018). https://doi.org/10.1186/s12974-018-1065-0Citation to related work
BMCHas part
Journal of Neuroinflammation, Vol. 15, Iss. 25ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/8746